Health ❯ Diseases ❯ Infectious Diseases
Symptoms Treatment Transmission Drug Resistance Plasmodium falciparum Severe Malaria Epidemiology Outbreaks Prevention Strategies Prevention and Treatment Malaria in Africa Plasmodium Species Prevention Methods Pathogen Resistance Mortality Rates RIFIN Proteins Statistics Cerebral Malaria Global Efforts Protein Research Control Strategies Malaria-protective Mutation Barriers to Accessing Services Diagnosis Funding and Control Elimination Strategies Vaccine Deployment South Sudan Plasmodium Parasites Malaria Vaccine Development Malaria Transmission Prevention Prevention Mosquito Control Genetic Engineering Anopheles Mosquito Mosquito-borne Diseases Child Health Research Impact on Vulnerable Populations Malaria Control Respiratory Infections Diagnosis and Treatment Medical Evacuation Ebola Artemisinin Resistance Vaccines Plasmodium berghei Hemorrhagic Fever Global Malaria Situation Prevention and Control Malaria Prevention Malaria Prevention Strategies
The ganaplacide–lumefantrine combo could reach patients in roughly 12 to 18 months if regulators grant approval.
